WO2011064437A2 - Vecteurs viraux et procédés utiles dans la préparation de gdnf - Google Patents

Vecteurs viraux et procédés utiles dans la préparation de gdnf Download PDF

Info

Publication number
WO2011064437A2
WO2011064437A2 PCT/ES2010/070778 ES2010070778W WO2011064437A2 WO 2011064437 A2 WO2011064437 A2 WO 2011064437A2 ES 2010070778 W ES2010070778 W ES 2010070778W WO 2011064437 A2 WO2011064437 A2 WO 2011064437A2
Authority
WO
WIPO (PCT)
Prior art keywords
gdnf
protein
hgdnf
cells
alphavirus
Prior art date
Application number
PCT/ES2010/070778
Other languages
English (en)
Spanish (es)
Other versions
WO2011064437A3 (fr
Inventor
Eduardo Ansorena Artieda
María Soledad AYMERICH SOLER
María José BLANCO PRIETO
Erkuden Casales Zoco
Elisa Garbayo Atienza
María Carmen MOLINA SAMPER
Cristian Smerdou Picazo
Original Assignee
Proyecto De Biomedicina Cima, S.L.
Instituto Científico Y Tecnológico De Navarra, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto De Biomedicina Cima, S.L., Instituto Científico Y Tecnológico De Navarra, S.A. filed Critical Proyecto De Biomedicina Cima, S.L.
Publication of WO2011064437A2 publication Critical patent/WO2011064437A2/fr
Publication of WO2011064437A3 publication Critical patent/WO2011064437A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un procédé pour la production et la purification de GDNF recombinant humain, ou d'un variant fonctionnellement équivalent de ce dernier, à l'aide de cellules eucaryotes qui comprennent un vecteur d'alphavirus qui comporte une séquence codant le GDNF humain recombinant, ou un variant fonctionnellement équivalent de ce dernier, relié fonctionnellement au promoteur sous-génomique qui dirige l'expression de la protéine chez un hôte d'expression approprié. La présente invention concerne également des vecteurs d'alphavirus et des cellules eucaryotes qui comprennent lesdits vecteurs d'alphavirus.
PCT/ES2010/070778 2009-11-26 2010-11-25 Vecteurs viraux et procédés utiles dans la préparation de gdnf WO2011064437A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931071 2009-11-26
ESP200931071 2009-11-26

Publications (2)

Publication Number Publication Date
WO2011064437A2 true WO2011064437A2 (fr) 2011-06-03
WO2011064437A3 WO2011064437A3 (fr) 2011-08-18

Family

ID=43902938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070778 WO2011064437A2 (fr) 2009-11-26 2010-11-25 Vecteurs viraux et procédés utiles dans la préparation de gdnf

Country Status (1)

Country Link
WO (1) WO2011064437A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001196A3 (fr) * 2010-06-28 2012-02-23 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues
ES2523016A1 (es) * 2013-05-20 2014-11-20 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
CN106754755A (zh) * 2015-11-23 2017-05-31 中国科学院武汉物理与数学研究所 一种西门利克森林病毒复制子及其在稀疏或精细神经元标记中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (fr) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Facteur neurotrophique a derivation gliale
EP0736099A1 (fr) 1993-12-23 1996-10-09 Zeneca Limited Expression de polyproteines a automaturation dans des plantes transgeniques
US5739026A (en) 1990-12-13 1998-04-14 Bioption Ab DNA expression systems based on alphaviruses
EP1386926A1 (fr) 2002-07-29 2004-02-04 Bioxtal Procédés de préparation de polypeptides marqués recombinants et leur utilisation
WO2008065225A2 (fr) 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vecteur viral et ses applications
WO2009089040A1 (fr) 2008-01-11 2009-07-16 Jaffrey Samie R Procédés pour l'expression de protéines dans des axones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143205A1 (en) * 2001-07-20 2003-07-31 Oxford Biomedica (Uk) Limited Alphavirus expression systems

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739026A (en) 1990-12-13 1998-04-14 Bioption Ab DNA expression systems based on alphaviruses
WO1993006116A1 (fr) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Facteur neurotrophique a derivation gliale
EP0736099A1 (fr) 1993-12-23 1996-10-09 Zeneca Limited Expression de polyproteines a automaturation dans des plantes transgeniques
EP1386926A1 (fr) 2002-07-29 2004-02-04 Bioxtal Procédés de préparation de polypeptides marqués recombinants et leur utilisation
WO2008065225A2 (fr) 2006-11-28 2008-06-05 Proyecto De Biomedicina Cima, S.L. Vecteur viral et ses applications
WO2009089040A1 (fr) 2008-01-11 2009-07-16 Jaffrey Samie R Procédés pour l'expression de protéines dans des axones

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Current protocols in molecular biology", vol. 2, September 2006, GREENE PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE
"Molecular cloning: a laboratory manual", 2001, COLD SPRING HARBOR
ALLANDER ET AL., J. BIOL. CHEM., vol. 269, pages 10891 - 8
ALTSCHUL, S. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ANSORENA E; GARBAYO E; LANCIEGO JL; AYMERICH MS; BLANCO-PRIETO MJ: "Production of highly pure human glycosylated GDNF in a mammalian cell line", INT J PHARM., vol. 385, no. 1-2, 29 January 2010 (2010-01-29), pages 6 - 11, XP026814015
BLASEY HD; LUNDSTROM K; TATE S; BERNARD AR: "Recombinant protein production using the Semliki Forest Virus expression system", CYTOTECHNOLOGY, vol. 24, 1997, pages 65 - 72, XP019236469, DOI: doi:10.1023/A:1007974121182
DAVIES, A.M.: "Neurotrophic", vol. 95, 1989, JOHN WILLEY AND SONS, LTD., article "Factor Bioassay Using Dissociated Neurons"
FORSMAN T; LAUTALA P; LUNDSTROM K; MONASTYRSKAIA K; OUZZINE M; BURCHELL B; TASKINEN J; ULMANEN I, LIFE SCI., vol. 67, no. 20, 6 October 2000 (2000-10-06), pages 2473 - 2484
GARBAYO E; ANSORENA E; LANCIEGO JL; AYMERICH MS; BLANCO-PRIETO MJ: "Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor", INT J PHARM, vol. 344, 2007, pages 9 - 15, XP022275347, DOI: doi:10.1016/j.ijpharm.2007.04.003
LATOUR ET AL., MOL. ENDOCRINOL., vol. 4, 1991, pages 1806 - 14
LILJESTR6M; GAROFF, BIO/TECHNOLOGY, vol. 9, 1991, pages 1356 - 1361
LILJESTROM P; GAROFF H ET AL.: "Current protocols in molecular biology", 1994, GREENE PUBLISHING ASSOCIATES AND WILEY INTERSCIENCE, article "Expession of proteins using Semliki Forest virus vectors", pages: 16.20.11 - 16.20.16
LILJESTROM, P.; H. GAROFF: "A new generation of animal cell expression vectors based on the Semliki Forest virus replicon", BIOTECHNOLOGY, vol. 9, 1991, pages 1356 - 61, XP000616021, DOI: doi:10.1038/nbt1291-1356
LIN ET AL., J.NEUROCHEM., vol. 63, 1994, pages 758 - 768
LIN LF; DOHERTY DH; LILE JD; BEKTESH S; COLLINS F: "GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons", SCIENCE, vol. 260, 1993, pages 1130 - 2
LUNDSTROM K.: "Semliki Forest virus vectors for large-scale production of recombinant proteins", METHODS MOL MED, vol. 76, 2003, pages 525 - 43
LUNDSTROM: "Methods in Molecular Medicine", vol. 76, HUMANA PRESS INC., article "Viral Vectors for Gene Therapy: Methods and Protocols"
MORETTO G; WALKER DG; LANTERI P; TAIOLI F; ZAFFAGNINI S; XU RY ET AL.: "Expression and regulation of glial-cell-line-derived neurotrophic factor (GDNF) mRNA in human astrocytes in vitro", CELL TISSUE RES, vol. 286, 1996, pages 257 - 62
PUSHKO ET AL., VIROLOGY, vol. 239, 1997, pages 389 - 401
PUSHKO, P.; PARKER, M.; LUDWIG, G. V.; DAVIS, N. L.; JOHNSTON, R. E.; SMITH, J. F.: "Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo", VIROLOGY, vol. 239, 1997, pages 389 - 401
RODRIGUEZ-MADOZ JR; PRIETO J; SMERDOU C: "Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas", MOL THER, vol. 12, 2005, pages 153 - 63, XP004974959, DOI: doi:10.1016/j.ymthe.2005.02.011
RYAN MD; DREW J.: "Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein", EMBO J, vol. 13, 1994, pages 928 - 33
SAJADI A; BENSADOUN JC; SCHNEIDER BL; LO BIANCO C; AEBISCHER P: "Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease", NEUROBIOL DIS, vol. 22, 2006, pages 119 - 29, XP024901603, DOI: doi:10.1016/j.nbd.2005.10.006
SMERDOU, C.; P. LILJESTROM.: "Two-helper RNA system for production of recombinant Semliki forest virus particles", J VIROL, vol. 73, 1999, pages 1092 - 8
VAN STEGG ET AL., J.VIROL., vol. 38, 1981, pages 728 - 736
WALSH G; JEFFERIS R: "Post-translational modifications in the context of therapeutic proteins", NAT BIOTECHNOL, vol. 24, 2006, pages 1241 - 52, XP055024914, DOI: doi:10.1038/nbt1252
WILSON ET AL., J. CLIN. ENDOCRINOL. METAB., vol. 86, pages 4504 - 11
XIONG ET AL., SCIENCE, vol. 243, 1989, pages 1188 - 1191
XIONG, C.; LEVIS, R.; SHEN, P.; SCHLESINGER, S.; RICE, C. M.; HUANG, H. V.: "Sindbis virus: an efficient, broad host range vector for gene expression in animal cells", SCIENCE, vol. 243, 1989, pages 1188 - 1191, XP000023527

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012001196A3 (fr) * 2010-06-28 2012-02-23 Proyecto De Biomedicina Cima, S.L. Vecteurs alphaviraux et leur utilisation pour l'expression de gènes hétérologues
ES2523016A1 (es) * 2013-05-20 2014-11-20 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
WO2014188042A1 (fr) * 2013-05-20 2014-11-27 3P Biopharmaceuticals Vecteurs alpha viraux et lignées cellulaires permettant la production de protéines recombinantes
US10011847B2 (en) 2013-05-20 2018-07-03 3P Biopharmaceuticals, S.L. Alphaviral vectors and cell lines for producing recombinant proteins
CN106754755A (zh) * 2015-11-23 2017-05-31 中国科学院武汉物理与数学研究所 一种西门利克森林病毒复制子及其在稀疏或精细神经元标记中的应用
CN106754755B (zh) * 2015-11-23 2020-07-21 中国科学院武汉物理与数学研究所 一种西门利克森林病毒复制子及其在稀疏或精细神经元标记中的应用

Also Published As

Publication number Publication date
WO2011064437A3 (fr) 2011-08-18

Similar Documents

Publication Publication Date Title
ES2890023T3 (es) Partículas alfavíricas y métodos de preparación
US11845939B2 (en) Compositions and methods for enhancing gene expression
JP5627464B2 (ja) アルファウイルス粒子を生成する方法
ES2223051T3 (es) Vectores de adnc de alfavirus.
US20230270841A1 (en) Coronavirus vaccine
US20220002682A1 (en) Alphavirus replicon particle
US20230044997A1 (en) Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
CA3183498A1 (fr) Replicon d'arn codant pour une proteine de spicule de coronavirus stabilisee
WO2011064437A2 (fr) Vecteurs viraux et procédés utiles dans la préparation de gdnf
US20230046606A1 (en) Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
US11873507B2 (en) Compositions and methods for expression of IL-12 and IL-1RA
Ansorena-Artieda et al. A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system
OA20123A (en) Alphavirus replicon particle.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10812863

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10812863

Country of ref document: EP

Kind code of ref document: A2